Influence of neonatal diethylstilbestrol
treatment on androgen and estrogen receptor levels in the mouse anterior prostate, ventral prostate and seminal vesicle.
-d6 showed 2 unstable peaks over time.
That was 1957, 11 years before the Food and Drug Administration warned doctors to stop prescribing diethylstilbestrol
, or DES.
A two-year study presented at the 93rd Annual Meeting of the American Association for Cancer Research (AACR) has confirmed the presence of synthetic compounds including the estrogenic drug diethylstilbestrol
(DES) in PC-SPES, the herbal supplement used by prostate cancer patients.
We recently studied a ThinPrep Papanicolaou test (Cytyc Corporation, Boxborough, Mass) from a 51-year-old woman with a history of exposure to diethylstilbestrol
who was 3 years postmenopausal and on hormone replacement therapy.
Half will get PC-SPES; the others will get an estrogen called DES, or diethylstilbestrol
The grandchildren of women who took the antimiscarriage drug diethylstilbestrol
(DES) are covered by the manufacturer's insurance policy and may recover damages, the Second Circuit recently held.
One possible source is linked to the hormone diethylstilbestrol
(DES), which many women took during pregnancy to prevent miscarriages.
At issue is the Swiss government's notification last July that it found traces of growth promotant diethylstilbestrol
(DES) in two of 100 samples of U.
TABLE I Examples of Known and Potential Endocrine Disrupters Substance Reference Diethylstilbestrol
5 DDT 20 PCBs 21 Estradiol-17b 22 Coumestrol 22 Equol 22 Zearalenone 22 3,9-Dihydroxybenz[a]anthracene 22 Kepone 22 DDE 23 Methoxychlor 20 Mirex 20 TCDD 24 Tributyltin 25, 26 Tamoxifen 27 Cadmium 28 Zearealonone 29 Benzo[a]pyrene 30 Lead 30 Arochlor 1254 30 Methyl mercury 31 PAHs 32 Polychlorinated dibenzo-p-dioxins 33 Polychlorinated dibenzofurans 33 Cyproterone acetate 29 Dibromochloropropane 29 Fenarimol 29 Nitrofen 29 Hexachlorophene 29 PBBs 29 Carbaryl 34 Aldrin 34 Chlordane 34 2,4-D 34 2,4,5-T 34 Zineb 34 Maneb 34
By utilizing this approach, GTx hopes that use will be devoid of many of the adverse effects of historical medical castration products such as diethylstilbestrol
(DES, an estrogen replacement therapy), and the luteinizing hormone receptor hormone (LHRH) agonists that form the current standard of care.
Previous studies have shown that perinatal exposure to the synthetic estrogen diethylstilbestrol
(DES) leads to feminization of the seminal vesicle (SV) in male mice, as evidenced by tissue hyperplasia, ectopic expression of a major estrogen-inducible uterine secretory protein lactoferrin (LF), and reduced expression of SV secretory IV protein (SVS IV).